Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

NORTHAMPTON, MA / ACCESS Newswire / April 29, 2025 / Gilead is committed to using its virology expertise to advance HIV ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

A New York doctor who treated HIV and AIDS patients sued Gilead for violating the False Claims Act with payments to doctors ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

NEW YORK, April 29 (Reuters) - Gilead Sciences (GILD.O), opens new tab agreed ... kickbacks to doctors who agreed to prescribe its HIV drugs. The settlement announced on Tuesday by U.S. Attorney ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women ...

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

AIDSVu analyses have revealed that although new HIV diagnoses have been declining throughout the ... we're not leaving any populations behind in this effort,” he says. Gilead Sciences, Inc. is a ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan ...